Perrigo Company plc Income (Loss) Attributable to Parent, before Tax
Perrigo Company plc (PRGO) reported Income (Loss) Attributable to Parent, before Tax of -$1.30 billion for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:IncomeLossAttributableToParent · last filed 2026-02-26
- Perrigo Company plc income (loss) attributable to parent, before tax for fiscal 2025 was -$1.30B.
- Perrigo Company plc income (loss) attributable to parent, before tax for fiscal 2024 was -$80.60M.
- Perrigo Company plc income (loss) attributable to parent, before tax for fiscal 2023 was -$8.40M.
- Perrigo Company plc income (loss) attributable to parent, before tax for fiscal 2022 was -$139.10M, a 153.77% decline from fiscal 2021.
| Period end | Income (Loss) Attributable to Parent, before Tax 12 month | Income (Loss) Attributable to Parent, before Tax 12 month as first filed |
|---|---|---|
| 2025-12-31 | -$1.30B 10-K · filed 2026-02-26 | |
| 2024-12-31 | -$80.60M 10-K · filed 2026-02-26 | |
| 2023-12-31 | -$8.40M 10-K · filed 2026-02-26 | |
| 2022-12-31 | -$139.10M 10-K · filed 2025-02-28 | |
| 2021-12-31 | $258.70M 10-K · filed 2024-02-27 | |
| 2020-12-31 | $5.90M 10-K · filed 2023-02-28 | -$149.40M 10-K · filed 2021-03-01 |
| 2019-12-31 | $148.00M 10-K · filed 2022-03-01 | $171.00M 10-K · filed 2020-02-27 |
| 2018-12-31 | $290.60M 10-K · filed 2021-03-01 | |
| 2017-12-31 | $280.10M 10-K · filed 2020-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |